


Appl. No. 10/783,092

Attorney Docket No. 13601-041

Amendment and Reply to Office Action of November 11, 2007

This listing of claims will replace all prior versions and listings of claims in the application:

1. **(Currently Amended)** A method for treating an individual suffering from increased bone turnover, said method comprising: (i) measuring at least one bone resorption marker or at least one bone formation marker to identify an individual having increased bone turnover; and (ii) administering to said individual a therapeutically active compound of formula (I)



or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof selected from the group consisting of TORE VI (4-hydroxy(deaminohydroxy)toremifene), TORE VII (4,4'-dihydroxy-(deaminohydroxy)toremifene), TORE XVIII (((deaminocarboxy)toremifene), TORE VIII (4-hydroxy(deaminocarboxy)toremifene) and TORE XIII (toremifene monophenol), in an amount effective to decrease bone loss, wherein the individual has (a) a bone resorption of at least 65 nmol/mmol Creatine, using amino terminal telopeptide of type I collagen measured in urine (U-NTX) as marker, and/or at least 680 microgram/mmol Creatine, using carboxy terminal telopeptide for type I collagen measured in urine (U-CTX) as marker, and (b) a bone formation of at least 170 microgram/l, using carboxy terminal propeptide of type I procollagen measured in serum (S-PICP) as marker and/or at least 84 microgram/l, using amino terminal propeptide of type I procollagen measured in serum (S-PINP) as marker.

2. **(Canceled)**

Appl. No. 10/783,092

Attorney Docket No. 13601-041

Amendment and Reply to Office Action of November 11, 2007

3. **(Previously Presented)** The drug formulation according to claim 1 wherein the compound of formula (I) is ospemifene.
4. **(Original)** The method according to claim 1, wherein the individual is a postmenopausal woman.
5. and 6. **(Canceled)**
7. **(Currently Amended)** The method according to ~~claim 6~~ claim 1 where the bone resorption, measured as U-NTX, is at least 70 nmol/mmol Creatine, and the bone formation, measured as S-PICP, is at least 180 microgram/l.
8. **(Original)** The method according to claim 7 where the bone resorption, measured as U-NTX, is at least 80 nmol/mmol Creatine.
9. **(Currently Amended)** The method according to ~~claim 5~~ claim 1 wherein the bone resorption has been measured using as a marker Crosslaps measured from serum.
10. **(Currently Amended)** The method according to ~~claim 5~~ claim 1 wherein the bone resorption has been measured using as a marker TRAP5b (Tartrate-resistant acid phosphatase subtype 5b) measured from serum.
11. **(Currently Amended)** The method according to ~~claim 5~~ claim 1 wherein the bone resorption has been measured using as markers a combination of Crosslaps and TRAP5b, both measured from serum.
12. **(Previously Presented)** The method according to claim 1, wherein the increased bone turnover is identified as a bone resorption marker and a bone formation marker having a value at least 5% higher than normal.

Appl. No. 10/783,092

Attorney Docket No. 13601-041

Amendment and Reply to Office Action of November 11, 2007

13. **(Previously Presented)** The method according to claim 1, wherein the increased bone turnover is identified as a bone resorption marker and a bone formation marker having a value at least 10% higher than normal.
14. **(New)** The method according to claim 1 wherein the compound of formula (I) is administered in an amount of from 30 mg to 90 mg/day.
15. **(New)** The method according to claim 1 wherein the compound of formula (I) is administered in an amount of 30 mg/day.
16. **(New)** The method according to claim 1 wherein the compound of formula (I) is administered in an amount of 60 mg/day.
17. **(New)** The method according to claim 1 wherein the compound of formula (I) is administered in an amount of 90 mg/day.
18. **(New)** The method according to claim 3 wherein the compound of formula (I) is administered in an amount of from 30 mg to 90 mg/day.
19. **(New)** The method according to claim 3 wherein the compound of formula (I) is administered in an amount of 30 mg/day.
20. **(New)** The method according to claim 3 wherein the compound of formula (I) is administered in an amount of 60 mg/day.
21. **(New)** The method according to claim 3 wherein the compound of formula (I) is administered in an amount of 90 mg/day.